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Abstract
This study aimed to profile the methylation statuses of CDH1/E-cadherin and five CpG island methylator pheno-
type (CIMP)-associated genes (p16, hMLH1, MINT1, MINT2, and MINT31) in gastric specimens of 47 Dalian long-
term residents with and 31 without gastric cancers (GCs). CIMP patterns were classified as CIMP-H with over
three methylated genes, CIMP-L with one to two methylated genes, and CIMP-N without methylation. Of
47 GC cases, 24 (51.1%) were CIMP-H, 18 (38.3%) were CIMP-L, and 5 (10.6%) were CIMP-N, whereas 5 of
21 (23.8%) premalignant lesions were CIMP-H and 15 (71.4%) were CIMP-L. CIMP-L was found in 75% (12/16)
of GC-adjacent mucosa and in 38.7% (12/31) of mucosa from GC-free patients. CDH1 methylation occurred in
48.9% (23/47) of cancer, in 23.8% (5/21) of premalignant, and in 25% (4/16) of noncancerous tissues and was
correlated with patients, age (P = .01), lymph node metastasis, and CIMP severity (P = .000–.028). Our results
demonstrated that the frequencies of CIMP-H in Dalian GCs, CIMP-L, and p16 methylation in GC-adjacent tissues
and in GC-free mucosa were much higher than those reported previously, indicating the elevated methylation pres-
sure in this GC high-risk region. The close correlation between CDH1 methylation and CIMP severity suggests the
necessity of their combination in GC prevention and earlier diagnosis.
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Introduction
Gastric cancer (GC) is one of the commonest malignancies in the
world and the major cause of cancer-related deaths in China [1].
There are several GC at-risk regions in China including Dalian, a
coastal and mountainous area located at the far south of Northeast
China. Although great effort has been paid in early prevention, diag-
nosis, and treatments, GC remains the first killer malignancy among
Dalian residents due to later diagnosis and lack of timely surveillance
measures. Multiple regional oncogenic factors have been proposed
during the past decades and diet habits are one of them [2]. Epide-
miologic studies demonstrated that people in this area were accus-
tomed to eating toasted or salted seafood and meat and preparing
preserved vegetables for the long winter season. These foods are rich
in gastrocarcinogens such as heterocyclic amines, polycyclic aromatic
hydrocarbons, and the well-known DNA methylators such as nitrite
and benzo(a)pyrene [3,4]. Apparently, a long-term consumption of
those foods may enhance the risk of genetic and epigenetic alterations
[5]. The high GC incidence and the traditional diet habits in this
region provide unique resource for investigating molecular aspect
of gastrocarcinogenesis.
DNA hypermethylation is the main machinery of epigenetic mod-
ulation of gene expression [6], especially for those induced by chemical
reagents [7,8]. DNA methylation happens in definite sequences be-
cause most of the methylation occurs on the cytosine of CpG site,
where the 5′–CG–3′ dinucleotide sequences appear infrequently in
the genome [9]. Because the 5′-promoter region of most genes are rich
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in CpG sequences [10], their methylation statuses determine the ac-
tivity of gene transcription [6,11]. A body of evidence demonstrated
that alterations of DNA methylation are closely related with cancer
formation, particularly with those raised from the organs exposed di-
rectly to environmental carcinogens [7]. Because methylated genes
rarely come alone but in group [12], Toyota et al. [13,14] introduced
the concept of CpG island methylator phenotype (CIMP) through the
study of aberrant methylation in colorectal and GCs, in which five to
seven methylator-sensitive genes were included for evaluating the
methylation statuses in cancers and for correlating the CIMP pat-
tern(s) with tumor risk and prevention [15,16].
So far, no comprehensive study has been performed on Dalian
GCs concerning CIMP profiling and its potential relationship with
the high GC incidence. Cyclooxygenase-2 (COX-2) has been shown
to play oncogenic roles during stepwise gastrocarcinogenesis, and its
expression is correlated with Helicobacter pylori infection, nuclear factor–
kappa B activation, and Wnt signaling [17–19]. However, despite
the existence of those COX-2 stimulators, COX-2 expression re-
mains infrequent in Dalian GCs due to hypermethylation of the
COX-2 promoter [20]. These data exclude the feasibility of COX-2–
targeting therapy for the prevention of Dalian GCs and, meanwhile,
highlight a hypermethylation-related gastrocarcinogenic option in this
GC at-risk region. We therefore hypothesized that, in addition to
COX-2 hypermethylation, global methylation status in gastric epithelial
cells might also be altered, which would be favorable for GC initiation
and progression. This hypothesis was tested in this study by profiling
the patterns of CIMP and CDH1 methylation in GC mass, GC sur-
rounding tissue, and grossly normal-looking epithelium of the surgical
specimens as well as the endoscopic gastric mucosa of GC-free patients.
Materials and Methods
Sample Collection and Treatment
Forty-seven surgical specimens from 34 male (mean age 61.6 ± 9.2
years) and 13 female (mean age 61.7 ± 8.8 years) GC patients were
selected from the Frozen Gastric Tissue Bank of the Cancer Institute,
Dalian Medical University (DMU), Dalian, PR China. Gastric mu-
cosa were obtained from 31 cancer-free patients and were provided
after the test of H. pylori infection and/or frozen section–based path-
ologic examination. All of the patients were long-term Dalian resi-
dents who never received preoperative chemotherapy. The tissue
samples were selected from the GC mass, GC surrounding tissue,
and grossly normal-looking epithelium of the surgical specimens.
They were trimmed to suitable sizes on ice, snap-frozen immediately
in liquid nitrogen, and stored at −85°C until use. All tissue prepara-
tions were completed within 20 minutes of tissue removal. After ob-
taining patients, consent, fresh gastric biopsies were collected from
either the Operation Rooms at DMU First Affiliated Hospital or
the Gastroendoscopic Department of DMU Second Affiliated Hos-
pital. The frozen tissue blocks were sectioned in 5-μm thickness,
fixed in cold acetone for 20 minutes, and subjected to hematoxylin
and eosin (H&E) staining for pathologic reexamination and tissue
composition evaluation. According to pathologic findings, the gastric
tissues were classified into well-differentiated intestinal-type gastric
cancer (i-GC), poorly differentiated diffuse-type gastric cancer
(d-GC), premalignant lesions including intestinal metaplasia and
atrophic gastritis, and normal-looking noncancerous mucosa. Mean-
while, a piece of placenta tissue was obtained after getting the per-
mission from a labored donor.
Genomic DNA Preparation and Sodium Bisulfite Treatment
Sample preparations were conducted according to the findings of
pathologic examination. When a tissue block showed uniform com-
position, it was sectioned directly for DNA isolation. When multiple
tissue components were found in the same tissue block, the border of
the target histologic region was marked precisely for cell type–defined
sample preparations with the manual dissection method established
in our laboratory [21,22]. In total, 16 to 24 pieces of 3-μm target fro-
zen fragments were collected after sectioning and were placed imme-
diately in a 1.5-ml Eppendorf tube containing 300 μl of TE buffer
(pH 8.0, 1% sodium dodecyl sulfate), digested with 5 μl of protein-
ase K (10 mg/ml), and subjected to conventional DNA extraction
using phenol/chloroform extraction and ethanol precipitation.
For chemical DNA modification, 5 μl of sample DNA (0.4 μg/μl)
was mixed with 40 μl of pure water, heated at 97°C for 6 minutes, and
interacted with 5 μl of 2 M NaOH at 37°C for 10 minutes, mixed
with 30 μl of freshly prepared 10 mM hydroquinone (H9003; Sigma,
St. Louis, MO) and 520 μl of 3 M sodium bisulfate (S9000; Sigma), and
then incubated at 50°C in darkness for 16 to 20 hours. The chemical-
modulated sample DNA was subjected to desalt purification using the
Wizard DNA Clean-Up System (A7280; Promega, Madison, WI). The
purified DNA was dissolved with 50 μl of pure water, mixed with
5.5 μl of 3 M NaOH at 37°C for 5 minutes, precipitated in ethanol,
and dissolved in 30 μl of pure water for use. A placenta DNA sample
was incubated with Sss1 methyltransferase (New England Biolabs
Inc., Beverly, MA) at 37°C for 4 hours followed by bisulfite treatment.
Methylation-Specific Polymerase Chain Reaction (PCR)
The sequences of methylation-specific PCR (MSP) primers and the
conditions of PCR reaction for individual genes are listed in Table 1
[23]. PCR amplifications were conducted using TaKaRa PCR am-
plification Kit (TaKaRa Biotechnology Inc. Dalian, China) by the fol-
lowing procedures: 30 μl of reaction solution was prepared, which
contains 3 μl of 10× buffer (Mg2+ Plus), 4 μl of 2.5 mM deoxyribo-
nucleotide triphosphate, 0.5 μl of respective 20 μM upstream and
downstream primers, 1 U Taq polymerase (5 U/μl), and 5 μl of
DNA template. The reaction condition was as follows: 94°C for 5 min-
utes; 94°C for 1 minute; 53 to 65°C for 1 minute and 72°C for 1 min-
ute for 35 to 40 cycles; and 72°C for 5 minutes. The PCR products
were separated in 6% polyacrylamide gel and were then observed and
photographed under UV illumination (BioSpectrumAC BioImaging
Systems; Ultra-Violet Products Inc., Upland, CA). Distilled pure water
was used as negative control [23] and the placenta DNA was treated
with Sss1 methyltransferase was used as positive control for methylated
allele in each of MSP reactions [24].
Criteria of CIMP Classification
In this study, p16, hMLH1, MINT1, MINT2, and MINT31 were
chosen and the hot loci of CpG island methylation in their promoter
regions were examined for CIMP identification. According to the
suggestion of Jean-Pierre Issa,s Laboratory [25], the grades of methyl-
ation were classified into three types: CIMP-high (CIMP-H) when
three to five genes were found with methylation; CIMP-low (CIMP-L)
when one or two genes were methylated; and CIMP-none (CIMP-N)
if none of the five genes was methylated. As indicated in Figure 1,
DNA samples isolated from the GC tissues of G-89-T and G-64-T
showed CIMP-H pattern, whereas their premalignant counterparts re-
vealed CIMP-L, and the noncancerous mucosa showed CIMP-N.
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Meanwhile, the CpG island methylation in the CDH1 promoter region
was checked using the PCR primers and reaction condition described
elsewhere [26] and the results were compared with CIMP patterns.
Collection and Analyses of CIMP-Related Data
The related clinical data were obtained from the clinical records
achieved in the Case Muniment Room of DMU Affiliated Hospitals.
Patients, gender, age, Lauren,s classification, the degree of tumor dif-
ferentiation, clinical stage/tumor, node, and metastasis staging, and
H. pylori infection were recorded. Mann-Whitney test was used to
analyze the distribution of three CIMP patterns as well as CDH1
methylation in GC, premalignant, and noncancerous groups, and
their relation with patients, gender, age, GC subtypes, tumor, node,
and metastasis staging, and H. pylori infection. Spearman relative
analysis was employed to evaluate the relation of the extent of CIMP
and CDH1 methylation.
Results
Differential Methylation Patterns of Five CIMP-Related
Genes during Stepwise Gastrocarcinogenesis
The same parameters (p16, hMLH1,MINT1,MINT2, andMINT31)
proposed by other investigators were employed here as CIMP-related
genes [23]. As shown in Table 2, MSP analysis performed on the tis-
sues obtained from gastrectomy specimens revealed that the incidences
of p16 methylation were 18.8% (3/16) in noncancerous, 57.1%
(12/21) in premalignant, and 63.8% (30/47) in GC tissues, respectively.
The detection rates of GCs and premalignant lesions were signifi-
cantly different with their noncancerous counterpart (P = .002 and P =
.020). The rates of hMLH1 methylation were 25% (4/16), 47.6%
(10/21), and 53.2% (25/47) in noncancerous, premalignant, and
Figure 1. Illustration of CIMP-H, CIMP-L, and CIMP-N and their distribution in different gastric tissues. U and M indicate the PCR prod-
ucts amplified with the primers for unmethylated and methylated sequences, respectively. d-GC, diffuse gastric cancer; i-GC, intestinal
gastric cancer; AG, chronic atrophic gastritis. Normal placenta DNA treated with Sss1 methyltransferase was used as positive control
(+) and distilled water without template DNA as negative control (−) for methylated loci.
Table 1. Primer Sequences and MSP Reaction Conditions for Individual Genes.
Gene Primer Sequence Annealing Temperature (°C)
p16 Methylated 65
Sense 5′–TTATTAGAGGGTGGGGCGGATCGC–3′
Antisense 5′–GACCCCGAACCGCGACCGTAA–3′
Unmethylated 60
Sense 5′–TTATTAGAGGGTGGGGTGGATTGT–3′
Antisense 5′–CAACCCCAAACCACAACCATAA–3′
MINT1 Methylated 55
Sense 5′–AATTTTTTTATATATATTTTCGAAGC–3′
Antisense 5′–AAAAACCTCAACCCCGCG–3′
Unmethylated 55
Sense 5′–AATTTTTTTATATATATTTTTGAAGTGT–3′
Antisense 5′–AACAAAAAACCTCAACCCCACA–3′
MINT2 Methylated 60
Sense 5′–TTGTTAAAGTGTTGAGTTCGTC–3′
Antisense 5′–AATAACGACGATTCCGTACG–3′
Unmethylated 60
Sense 5′–GATTTTGTTAAAGTGTTGAGTTTGTT–3′
Antisense 5′–CAAAATAATAACAACAATTCCATACA–3′
MINT31 Methylated 60
Sense 5′–TGTTGGGGAAGTGTTTTTCGGC–3′
Antisense 5′–CGAAAACGAAACGCCGCG–3′
Unmethylated 64
Sense 5′–TAGATGTTGGGGAAGTGTTTTTTGGT–3′
Antisense 5′–TAAATACCCAAAAACAAAACACCACA–3′
hMLH1 Methylated 60
Sense 5′–GATAGCGATTTTTAACGC–3′
Antisense 5′–TCTATAAATTACTAAATCTCTTCG–3′
Unmethylated 60
Sense 5′–AGAGTGGATAGTGATTTTTAATGT–3′
Antisense 5′–ACTCTATAAATTACTAAATCTCTTCA–3′
CDH1 Methylated 57
Sense 5′–TTAGGTTAGAGGGTTATCGCGT–3′
Antisense 5′–TAACTAAAAATTCACCTACCGAC–3′
Unmethylated 53
Sense 5′–TAATTTTAGGTTAGAGGGTTATTGT–3′
Antisense 5′–CACAACCAATCAACAACACA–3′
The primer sequences and reaction conditions were cited from Park et al. [23] and Herman et al. [26].
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GC groups, respectively. In the case of MINTs, the methylation rates
of MINT1 were 25% (4/16) in noncancerous, 42.9% (9/21) in pre-
malignant, and 44.7 (21/47) in GC groups; MINT2, 12.5% (2/16)
in noncancerous, 33.3% (7/21) in premalignant, and 40.4 (19/47)
in GC groups; and MINT31, 18.8% (3/16) in noncancerous, 14.3%
(3/21) premalignant, and 25.5 (12/47) GC groups. Unlike the results
of p16 analysis, Mann-Whitney test revealed that no significant differ-
ence between the hMLH1, MINT1, MINT2, or MINT31 methylation
rates could be found among the three histologic groups when they
were compared in pair (P > .05).
Distinct CIMP Patterns of GC, Premalignant,
and Noncancerous Groups
As summarized in Figure 2, and Table 3, the frequencies of CIMP-H
were 51.1% (24/47) in GC group, 23.8% (5/21) in premalignant le-
sions, and 0% (0/16) in noncancerous mucosa. CIMP-L was 38.3%
(18/47) in GCs, 71.4% (15/21) in premalignant, and 75% (12/16)
in noncancerous tissues, respectively. CIMP-N was 10.6% (5/47) in
GCs, 4.8% (1/21) in premalignant, and 25% (4/16) in noncancerous
tissues. The statistical analyses revealed that the incidences of CIMP-H
were significantly different (P = .001) between premalignant (23.8%,
5/21) and GC groups (51.1%, 24/47). However, no statistical difference
could be established between diffuse GCs (59.3%, 16/27) and intestinal
GCs (40%, 8/20) (P = .282) and between the primary GCs with (50%,
15/30) and without lymph node metastases (50%, 5/10) (P = .435).
Frequent CIMP-L in the Mucosa of GC-Free Patients
Among the 31 gastric biopsies obtained from GC-free patients, 9
were found with mild and 22 were with moderate to severe chronic
gastritis (Figure 3). Furthermore, 20 were positive in H. pylori infec-
tion, 10 were negative, and 1 was without relevant record. There
were nine cases (29%) with p16 methylation, three (9.7%) with
hMLH1, two (6.5%) with MINT1, none with MINT2, and three
(9.7%) with MINT31. None of those samples exhibited CIMP-H,
whereas 12/31 (38.7%) were found with CIMP-L. Distribution of
CIMP-L in mild (2/9, 22.2%) and severe gastritis (10/22, 45.5%)
was different but without statistical significance (P = .367). In com-
parison with the data obtained from the noncancerous mucosa of
GC-bearing patients, the frequencies of hMLH1, MINT1, MINT2,
and MINT31 methylation were significantly lower (P = .000–.008)
except that of p16 methylation (P = .323).
No Relevance of CIMP Patterns with Patients , Gender,
Age, and H. pylori Infection
Analysis of CIMP patterns in male and female GC patients re-
vealed that CIMP-H was 47.1% (16/34), CIMP-L was 38.2%
(13/34), and CIMP-N was 14.7% (5/34) among male patients,
and 61.5% (8/13), 38.5% (5/13), and none among females, respec-
tively (Table 3). No significant difference of these parameters could
be established between the two groups (P = .317). The 47 GC cases
checked here were divided into two age groups: the younger (less
Table 2. Methylation Statuses of p16, hMLH1, MINT1, MINT2, MINT31, and CDH1 in Dif-
ferent Gastric Tissues.
Locus Methylation Frequencies P
Endoscopic
(n = 31)
Noncancerous
(n = 16)
Premalignant
(n = 21)
GC (n = 47)
p16 29% (9/31) 18.8% (3/16) 57.1% (12/21) 63.8% (30/47) .008
hMLH1 9.7% (3/31)* 25% (4/16) 47.6% (10/21) 53.2% (25/47) .151
MINT1 6.5% (2/31)* 25% (4/16) 42.9% (9/21) 44.7% (21/47) .375
MINT2 0% (0/31)* 12.5% (2/16) 33.3% (7/21) 40.4% (19/47) .126
MINT31 9.7% (3/31)* 18.8% (3/16) 14.3% (3/21) 25.5% (12/47) .56
CDH1 9.7% (3/31)* 25% (4/16) 23.8% (5/21) 48.9% (23/47) .031
*Significant difference of methylation incidences between the noncancerous mucosa of the patients
with and without gastric cancers (Mann-Whitney test, P = .000–.008).
Figure 2. Profiling of CIMPs in gastric cancers raised from Dalian, China.▪, the locus with methylation among GC tissues; , the locus with
methylation among premalignant/noncancerous gastric mucosa; and□, the locus withoutmethylation.N.A., tissue sample was not available.
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than 50 years old) and the elder (over 50 years old) groups [12]. The
incidences of i-GC and d-GC were 50% (6/12) and 50% (6/12)
in the younger and 40% (14/35) and 60% (21/35) in the elder
group, respectively, showing similar i-GC and d-GC incidences of
the two groups (P = .157). Of 12 younger cases, 4 (33.4%) were
found with CIMP-H, 7 (58.3%) with CIMP-L, and 1 (8.3%) with
CIMP-N, whereas 20 (57.2%) of 35 elder GC patients were with
CIMP-H, 11 (31.4%) with CIMP-L, and 4 (11.4%) with CIMP-N.
Although CIMP-H frequency of the elder patients was higher than
that of the younger patients, this difference had no statistical signif-
icance (P = .154).
Among the 47 GC cases, 8 were diagnosed as H. pylori–positive
(HP+) and 5 as H. pylori–negative (HP−). Notably, all of the HP−
cases showed CIMP-H in comparison with 37.5% (3/8) of CIMP-
H in HP+ tissues. However, a statistical difference of CIMP-H inci-
dences could not be established (P = .079) between the two groups
due to the limited case number. To further address this issue, the test
of H. pylori infection was performed on the noncancerous mucosa of
30 GC-free patients, which revealed that 20 were found with and 10
without H. pylori infection. The same frequencies of CIMP-L (40%)
and CIMP-N (60%) were found in both HP+ and HP− groups.
Close Correlation of CIMP-H with CDH1 Hypermethylation
CDH1 promoter methylation was found in 48.9% (23/47) of GC
samples, and 75% (18/24) of this methylation occurred in CIMP-H
and 21.7% (5/23) in CIMP-L/N GC group, revealing a significant
difference of CDH1 methylation rates between the two groups (P =
.000; Table 3). The incidences of CDH1 methylation were appar-
ently lower in the premalignant (23.8%; 5/21) and noncancerous tis-
sues (25%; 4/16) of GC patients (P = .031). About 35% (7/20) of
i-GC were found with methylated CDH1 in comparison with 59.3%
(16/27) in d-GC (P = .100), indicating that the loss of E-cadherin
due to the increased CDH1 methylation in d-GCs may lead to the
diffuse phenotype. Additionally, CDH1 methylation was found
in 63.3% (19/30) of primary GCs with lymph node metastases,
whereas in 20% (2/10) of those without lymph node metastases
(P = .028). CDH1 methylation was also correlated with the patients,
age (P = .010), because its frequencies were apparently different in
the younger (16.7%, 2/12) and the elder GC groups (60%, 21/35).
In contrast, no statistical significance of CDH1 methylation inci-
dences was found between male (47.1%, 16/34) and female
(53.8%, 7/13) patients (P = .108). The results from the noncancer-
ous mucosa of 31 GC-free patients revealed that 3 cases (9.7%) were
found with CDH1 methylation, and all of them fell into the elder
and CIMP-L groups.
Discussion
Altered gene silencing due to DNA hypermethylation is a univer-
sal epigenetic event in great majority of human malignancies, which,
unlike the situation of hereditary diseases, happens to multiple genes
in cancer cells and the genes affected usually vary in chemical- and
disease-dependent fashions [3,4,27]. It is therefore necessary to elu-
cidate the methylation statuses of a panel of representative genes in
an individual disease. To achieve this goal, CIMP was introduced by
Toyota et al. [13]. Data from gastroenterological cancers revealed that a
combination of MINT1, MINT2, and MINT31 with tumor suppres-
sor p16 and mismatch repair gene hMLH1 is suitable in evaluating
the general methylation status in these sorts of tumors [14,25,28].
To make our results more comparable with the published data, we em-
ployed this evaluation system to check the unknown CIMP pattern in
Dalian GCs and to see whether the CIMP pattern here was different
from those identified in other places.
To have a clearer view in the correlation of DNA methylation with
GC formation in this GC high-risk region, different histologic tissues
of GC surgical specimens and the endoscopic gastric mucosa of GC-
free patients were collected and examined. It has been believed that
GC-adjacent noncancerous mucosa and chronic gastritis rarely had
p16 (0–10%) and hMLH1 (0–1.7%) methylation, even in the case
of GCs of high-risk regions [29,30]. In contrast, the methylation in-
cidences of p16 and hMLH1 in the same tissue types of Dalian GC
patients were 18.8% and 25%, respectively. Accordingly, the methyl-
ation rates of MINT1 (25%) and MINT2 (12.5%) in those samples
were also higher than the ones (5% and 7%) reported by other in-
vestigators [28]. These results implicate the existence of certain epi-
genetic variations in different GC high-risk regions and the elevated
methylation pressure in Dalian region presumably due to its epide-
miologic features as mentioned in the Introduction section. This
speculation was further supported by the data obtained from the in-
flammatory mucosa of 31 GC-free patients, because 29% of them
were found with p16 methylation, 9.7% with hMLH1, and even
GC-associated MINT1 and MINT31 methylation could be detected
in the rates of 6.5% and 9.7%, respectively. Moreover, p16 and
MINT1 or MINT31 methylation appeared even in the mucosa of
18-year-old male and 27-year-old female patients, and hMLH1 in
a 26-year-old male. If we suppose the relatively high p16 and
hMLH1 methylation incidences in GC-adjacent mucosa is somewhat
influenced by the neoplastic changes and/or tumorigenic microenvi-
ronment, the findings from GC-free patients reflect the frequent pre-
existence of abnormally methylated genes in this GC high-risk
population. Because p16 plays important roles in controlling cell
outgrowth [31] and hMLH1 in repairing the nucleotide sequences
Table 3. Differential CIMP and CDH1 Methylation Patterns during Stepwise Gastrocarcinogenesis
and Their Correlation with Patients, Personal Parameters.
Parameters No. CIMP P CDH1*
Methylation (%)
P
H (%) L (%) N (%)
Gender
Male 34 16 (47.1) 13 (38.2) 5 (14.7) .317 16 (47.1) .108
Female 13 8 (61.5) 5 (38.5) 0 (0) 7 (53.8)
Age (years)
< 50 12 4 (33.4) 7 (58.3) 1 (8.3) .154 2 (16.7) .010
≥ 50 35 20 (57.2) 11 (31.4) 4 (11.4) 21 (60)
Histology
Noncancerous 16 0 (0) 12 (75) 4 (25) .001 4 (25) .031
Premalignant 21 5 (23.8) 15 (71.4) 1 (4.8) 5 (23.8)
Cancer 47 24 (51.1) 18 (38.3) 5 (10.6) 23 (48.9)
d-GC 27 16 (59.3) 8 (29.6) 3 (11.1) .282 16 (59.3) .100
i-GC 20 8 (40) 10 (50) 2 (10) 7 (35)
Differentiation
Poor 32 16 (50) 13 (40.6) 3 (9.4) .236 19 (59.4) .335
Well 7 4 (57.1) 2 (28.6) 1 (14.3) 2 (28.6)
Lymph node
metastasis
+ 30 15 (50) 11 (36.7) 4 (13.3) .435 19 (63.3) .028
− 10 5 (50) 5 (50) 0 (0) 2 (20)
H. pylori infection
+ 8 3 (37.5) 3 (37.5) 2 (25) .079 3 (37.5) .112
− 5 5 (100) 0 (0) 0 (0) 4 (80)
*Significant difference of CDH1 methylation incidences between CIMP-H and CIMP-L/N groups
(Spearman relative analysis, P = .000).
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damaged/altered by external and intrinsic factors [32], it is reason-
able to suppose that the cells without those proteins may gain longer
life span and/or more chance of additional genetic aberrations.
The CIMP data from previous GC studies revealed that the fre-
quencies of CIMP-H were from 31% to 51% in GC tissues, whereas
only 4% to 16% in GC-adjacent premalignant or normal mucosa
[28,33]. It was therefore proposed that CIMP-H happened in the
later stage of gastrocarcinogenesis. In this study, CIMP-H was found
preferentially in Dalian GCs (51.1%) and at a higher rate among
premalignant lesions (23.8%, 5/21), suggesting the accumulation
of multiple loci methylations during malignant transformation. Al-
though none of the noncancerous mucosa exhibited CIMP-H, the
incidence of CIMP-L (75%) in those tissues was remarkably higher
than the ones (17–38%) reported previously [28,33,34] because of
the early appearance of methylation(s) of the five checked genes.
Based on the low frequency of COX-2 expression due to promoter
hypermethylation in Dalian GCs, we had assumed the possible high
methylation background in this GC high-risk population [20]. The
results of the current study provided further supporting data for this
speculation and motivated us to check whether the gastric mucosa of
GC-free patients showed the similar methylation tendency.
The data about CIMP patterns in different gastric lesions have
been accumulated in recent years, including the ones from other
GC popular regions [33,34]. However, a simultaneous analysis on
gastric samples from the patients with and without GCs in a high-
risk population has been rarely reported. This work was conducted
using endoscopic biopsies of 31 GC-free outpatients. Similar with
the situation of GC-adjacent noncancerous mucosa, a high rate
(38.7%) of CIMP-L and absence of CIMP-H was found in those
samples. It was noted that 2 of 12 CIMP-L cases appeared in the
patients with mild gastritis and 7 in the patients are less than 50 years
old. These findings thus provide additional evidence for the high
methylation status of Dalian long-term residents, and further hold
the notion that DNA methylation may occur at the early stage of
gastrocarcinogenesis. Although the local factor(s) leading to the high
methylation status remains to be figured out, early detection of
methylation-sensitive genes such as p16 and exploration of reliable
method to erase the methylation from those genes would have poten-
tial value in GC prevention of this region.
Generally, the genes affected by hypermethylation can be classi-
fied into two categories: cancer-associated genes as Type-C and age-
related genes as Type-A [13]. The five genes used for CIMP profiling
Figure 3. Personal backgrounds and CIMP statuses of gastric biopsies of GC-free patients. The dark and light blocks indicate the genes
with and without methylation, respectively. M-CG, mild chronic gastritis; S-CG, moderate to severe chronic gastritis; N.A., the record of
H. pylori test was not available.
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here are Type-C genes [35] that are sensitive to environmental meth-
ylators [25]. However, their responses to other GC-related factors
like H. pylori infection are still in dispute. Maekita et al. [36] found
high levels of aberrant DNA methylation in H. pylori–infected gas-
tric samples, whereas Kang et al. [30] reported that this epigenetic
event was unrelated with H. pylori infection. The results obtained
from the gastric samples of both GC-bearing and GC-free patients
revealed that the CIMP status is related neither with H. pylori infec-
tion nor with patients, age, gender, as well as GC subtypes. These
data thus suggest that Type-C genes are more suitable for CIMP pro-
filing because of their preferential methylations in cancer-associated
lesions regardless of the differences of other personal factors. Addi-
tionally, our results indicate two possibilities: 1) the gastrocarcino-
genic effect(s) of H. pylori may not depend on DNA methylation
pathway or 2) certain powerful methylation element(s) might exist
universally and cause hypermethylation of Type-C genes in Dalian
gastric samples irrespective of the presence or absence of H. pylori
infection. In this context, more careful evaluation will be required
to address the association of HP infection and increased severity of
DNA methylation in GC high-risk regions.
Downregulation of CDH1 is a typical malignant biomarker ob-
served in a wide variety of cancers including GCs [37]. Multiple ge-
netic factors can inhibit CDH1 expression, and hypermethylation in
CDH1 promoter region is one of the main reasons [38]. Because
CDH1 methylation usually appeared in elder patients, it was re-
garded as a kind of age-related methylation (Type-A methylation)
[35]. In parallel with CIMP analysis, the status of CDH1 methyla-
tion was checked here to elucidate the potential link of CDH1 meth-
ylation to CIMP patterns and to see whether this sort of methylation
occurred earlier or more frequently in a GC high-risk population. In
agreement with previous reports [35,39,40], we found increased fre-
quency of CDH1 methylation in GC samples and the gastric mucosa
of GC-free patients in an age-related pattern. However, it is difficult
to conclude the causality of CDH1 methylation with gastrocarcino-
genesis because: 1) the methylation event of CDH1 unnecessarily
occurs concurrently in GC and noncancerous tissues of the same pa-
tients and 2) CDH1 methylation is frequently found in CIMP-H GC
cases. Moreover, CDH1 methylation is closely related with GC dis-
semination because of its presence in 63.3% (19/30) of primary
GCs with lymph node metastases, but only 20% (2/10) in those
without lymph node metastases. All these data suggest the cancer-
promoting feature of CDH1 downregulation/silencing and the exis-
tence of other methylation element(s) in the transformed cells beyond
cell aging. Therefore, we would rather regard CDH1 methylation
as Mixed type (Type-M) because of its compatibility with age- and
cancer-associated features. To make the results more informative and
substantial, a combination of CDH1 with Type-C genes would be
necessary in CIMP profiling.
In summary, our comprehensive CIMP profiling revealed a high
CIMP-H incidence in GC samples and more frequent CIMP-L in
premalignant and noncancerous mucosa of the patients with and
without GCs, suggesting the persistent methylation pressure and in-
creased CIMP grade in this GC at-risk region. Among the five
CIMP-associated genes so far checked, p16 seems more sensitive to
methylator(s) because of its overall methylation rate and the earlier
onset of its methylation in stepwise gastrocarcinogenesis. CDH1
methylation was closely related with either aging or malignant phe-
notypes of gastric epithelial cells. Therefore, an integration of CDH1
with conventional CIMP-related genes is recommended in methyla-
tion assay. Because several options for profiling methylation patterns
of GCs have been available [14,28,30,34], it would be worthwhile to
compare their applicability in GC risk assessment of the Dalian re-
gion based on the current study.
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